No, what we're saying in that is when we look around the world at countries that have implemented that kind of program, it becomes very much a cost containment strategy as opposed to a patient outcome strategy.
What we've seen, whether it's New Zealand or the U.K., are restrictions on the number of drugs being covered, for good reason. Part of the reason you move to this system is to try to get volume discounts on purchasing. Obviously you can't get volume discounts if you're not trying to consolidate the drug expenditure.